Ensysce Biosciences, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Adage Capital Management and its principals have disclosed a 3.15% passive beneficial ownership stake in Ensysce Biosciences, Inc.
NASDAQ
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has filed an amendment to disclose a passive 3.7% beneficial ownership stake in Ensysce Biosciences, Inc.
NASDAQ
Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has disclosed a beneficial ownership of 5.32% in Ensysce Biosciences, Inc.'s common stock.
NASDAQ
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have filed an amended Schedule 13G, confirming their beneficial ownership of 5.3% of Ensysce Biosciences, Inc.'s common stock.
NASDAQ
SCHEDULE 13G/A: RA Capital Management Divests Entire Stake in Ensysce Biosciences, Filing Amended Schedule 13G
RA Capital Management, along with its affiliates, has reported a complete divestment of its beneficial ownership in Ensysce Biosciences, Inc., reducing its stake to 0% as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: Anson Funds Discloses 2.1% Stake in Ensysce Biosciences
Anson Funds Management LP and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 2.1% in Ensysce Biosciences, Inc. as of December 31, 2024.
NASDAQ
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has filed an amended Schedule 13G disclosing a passive 0.4% beneficial ownership in Ensysce Biosciences, Inc. as of December 31, 2024.